文献速递脊柱关节炎

生物改善病情抗风湿药在晚发型中轴型脊柱关节炎中的生存分析——来自葡萄牙登记处的数据

Biologic disease-modifying antirheumatic drugs survival in late-onset axial spondyloarthritis - data from a Portuguese registry.
PubMed 文献 · Rheumatology (Oxford) · 2025-01-01

这项回顾性多中心全国队列研究利用葡萄牙风湿病登记处数据,以45岁为界定义晚发型中轴型脊柱关节炎(lo-axSpA),纳入2256例患者,其中260例(11.5%)为lo-axSpA。晚发型组在基线及3、6、12个月时疾病活动度评分显著更高,但两组疾病活动度评分呈比例下降;晚发型组治疗最初12个月停药率更高,但lo-axSpA与治疗停药风险增加无关。两组停药主要原因均为疗效不佳,感染和其他不良事件发生率低。

要点

  • 2256例患者中260例(11.5%)为晚发型中轴型脊柱关节炎(lo-axSpA),以45岁为界定义。
  • 晚发型组基线及3、6、12个月疾病活动度评分显著更高,但两组评分呈比例下降。
  • 晚发型组治疗最初12个月停药率更高,但lo-axSpA与停药风险增加无关。

核心结论

  • 本研究表明lo-axSpA与治疗疗效降低或安全性受损无关。

研究设计与样本

  • 回顾性、多中心、全国队列研究,使用葡萄牙风湿病登记处数据,以45岁为界定义lo-axSpA,纳入2256例患者,其中260例(11.5%)为lo-axSpA。

主要发现

  • 晚发型组在基线、3、6和12个月时强直性脊柱炎疾病活动度评分、Bath强直性脊柱炎疾病活动度指数和Bath强直性脊柱炎功能指数评分均显著更高。
  • 尽管存在上述差异,两组疾病活动度评分呈比例下降,表明疾病活动度随时间持续降低。
  • 晚发型组治疗最初12个月停药率更高,但lo-axSpA与治疗停药风险增加无关。
  • 两组治疗停药的主要原因均为疗效不佳,整个队列中感染和其他不良事件发生率低。

关键数值与推荐

  • 以45岁为界定义lo-axSpA。
  • 纳入2256例患者,其中260例(11.5%)为lo-axSpA。
  • 药物生存分析评估时间为12个月。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Although axial spondyloarthritis (axSpA) typically begins before age 45, late-onset axSpA (lo-axSpA) has been widely recognized. While existing literature describes this subgroup, data on therapeutic approaches remain limited. Therefore, we aimed to evaluate the efficacy and safety of biologic DMARDs in patients with lo-axSpA. METHODS: We conducted a retrospective, multicentre, national cohort study using data from the Rheumatic Diseases Portuguese Register. A cut-off age of 45 years was applied to define lo-axSpA. Group differences between early- and late-onset disease activity scores were evaluated, and drug survival was assessed over 12 months. Predictors of drug discontinuation were identified using a Cox proportional hazards model. RESULTS: In total, 2256 patients were included, of whom 260 (11.5%) had lo-axSpA. Patients with late-onset disease exhibited significantly higher scores in the Ankylosing Spondylitis Disease Activity Score, Bath Ankylosing Spondylitis Disease Activity Index and Bath Ankylosing Spondylitis Functional Index at baseline, 3, 6 and 12 months. Despite these differences, both groups showed proportional reductions in disease activity scores, indicating a continuous decrease in disease activity over time. Although the late-onset group had a higher discontinuation rate during the first 12 months of treatment, lo-axSpA was not associated with an increased risk of therapy discontinuation. The primary reason for treatment discontinuation in both groups was inefficacy, with low rates of infections and other adverse events observed across the cohort. CONCLUSION: Our study demonstrated that lo-axSpA is not associated with reduced treatment efficacy or compromised safety.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Silva SP, Monteiro B, Pinto Oliveira C, et al. Biologic disease-modifying antirheumatic drugs survival in late-onset axial spondyloarthritis - data from a Portuguese registry. Rheumatology (Oxford). 2025. PMID: 40168107. doi:10.1093/rheumatology/keaf176

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。